Response to: “commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of peyronie’s disease: a retrospective cohort study”

Access through your institution Buy or subscribe We appreciate the commentary by Manfredi et al. on our study investigating the impact of phosphodiesterase type 5 inhibitors (PDE5is) on

Peyronie’s disease (PD) in the active phase [1]. The attention devoted to non-surgical interventions in PD in recent years highlights a growing recognition of the need for effective

non-invasive treatments for this condition. This increased focus may reflect a broader shift in medical practice towards holistic patient care, emphasizing options beyond surgical

intervention. Despite the paucity of clinical studies, PDE5is hold promise as a viable, safe, and practical approach to managing the condition, potentially offering relief and influencing

its progression [2, 3]. With their generally well-tolerated nature and favorable safety profile [4], PDE5is emerge as an appealing choice for PD management. In our retrospective cohort

study, 133 patients with PD in the active phase were included. Group 1 (_n_ = 101) received continuous treatment with PDE5is, while Group 2 (_n_ = 32) received no treatment. The curvature

progression was recorded over a mean follow-up of approximately one year. Between the first and last observations, Group 1 exhibited a mean penile curvature change of + 0.87° (95% CI: −1.8,

3.5), whereas Group 2 experienced a larger increase of + 5.72° (95% CI: 1.4, 10). Although there was a numerical difference in curvature progression, it did not reach statistical

significance (_p_ = 0.07), and the variance was small compared to what would be considered clinically meaningful [5]. Meanwhile, Group 1 exhibited a shorter mean duration of pain of 9.1

months (SD 4.7), compared to Group 2 reporting a mean pain duration of 12.2 months (SD 6.5) (_p_ = 0.04). This is a preview of subscription content, access via your institution ACCESS

OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on

SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about

institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Manfredi C, Bologna E, Licari LC. Commentary on “Phosphodiesterase type 5 inhibitors do not prevent

curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”. Int J Impot Res. 2023;1–2.

https://doi.org/10.1038/s41443-023-00811-4. * Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J

Sex Med. 2011;8:1472–7. Article  CAS  PubMed  Google Scholar  * Spirito L, Manfredi C, La Rocca R, Napolitano L, Di Girolamo A, Capece M, et al. Daily low-dose tadalafil may reduce the

penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis. Int J Impot Res. 2022. https://doi.org/10.1038/S41443-022-00651-8. * Huang

SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. Pharm Ther. 2013;38:407. Google Scholar  * Durukan E, Kraglund R, Rashid SA, Thorkilgaard T,

Jensen CFS, Fode M. Phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s Disease: a retrospective cohort

study. Int J Impot Res. 2024: 1–4. https://doi.org/10.1038/s41443-023-00810-5. * Joseph J, Ziegelmann MJ, Alom M, Savage J, Köhler TS, Trost L. Outcomes of RestoreX penile traction therapy

in men with Peyronie’s disease: results from open label and follow-up phases. J Sex Med. 2020;17:2462–71. Article  PubMed  Google Scholar  * Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes

A, Christopher N, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106:1178–1180. Article  PubMed  Google Scholar  Download

references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Urology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark Emil Durukan, Christian

Fuglesang Skjødt Jensen & Mikkel Fode * Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark Emil Durukan & Mikkel Fode Authors * Emil Durukan View author

publications You can also search for this author inPubMed Google Scholar * Christian Fuglesang Skjødt Jensen View author publications You can also search for this author inPubMed Google

Scholar * Mikkel Fode View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS ED: Manuscript writing and editing, CFSJ: Manuscript reviewing and

editing, MF: Manuscript reviewing, editing and supervision. CORRESPONDING AUTHOR Correspondence to Emil Durukan. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing

interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Durukan, E., Jensen, C.F.S. & Fode, M. Response to: “Commentary on: phosphodiesterase type 5 inhibitors do not

prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease: a retrospective cohort study”. _Int J Impot Res_ 36, 297–298 (2024).

https://doi.org/10.1038/s41443-024-00872-z Download citation * Received: 26 February 2024 * Revised: 04 March 2024 * Accepted: 04 March 2024 * Published: 22 March 2024 * Issue Date: May 2024

* DOI: https://doi.org/10.1038/s41443-024-00872-z SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link

is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative